Grant of Interim Extension of the Term of U.S. Patent No. 4,826,811; PolyHeme® (Acellular Red Blood Cell Substitute), 35627 [E6-9767]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 119 / Wednesday, June 21, 2006 / Notices
Comments must be received by
July 21, 2006.
ADDRESSES: The draft Prospectus is
posted on the CCSP Program Office web
site. The web addresses to access the
draft Prospectus is:
Product 4.3 (Resources):
https://www.climatescience.gov/Library/
sap/sap4–3/default.htm
Detailed instructions for making
comments on the draft Prospectus is
provided with the Prospectus.
Comments should be prepared in
accordance with these instructions.
FOR FURTHER INFORMATION CONTACT:
Vanessa Richardson, Climate Change
Science Program Office, 1717
Pennsylvania Avenue NW., Suite 250,
Washington, DC 20006, Telephone:
(202) 419–3465.
SUPPLEMENTARY INFORMATION: The CCSP
was established by the President in 2002
to coordinate and integrate scientific
research on global change and climate
change sponsored by 13 participating
departments and agencies of the U.S.
Government. The CCSP is charged with
preparing information resources that
support climate-related discussions and
decisions, including scientific synthesis
and assessment analyses that support
evaluation of important policy issues.
The Prospectus addressed by this notice
provides a topical overview and
describes plans for scoping, drafting,
reviewing, producing, and
disseminating one of 21 final synthesis
and assessment Products that will be
produced by the CCSP.
DATES:
Dated: June 15, 2006.
Conrad C. Lautenbacher, Jr.,
Vice Admiral, U.S. Navy (Ret.), Under
Secretary of Commerce for Oceans and
Atmosphere.
[FR Doc. E6–9745 Filed 6–20–06; 8:45 am]
BILLING CODE 3510–12–S
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2006–0035]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,826,811;
PolyHeme (Acellular Red Blood Cell
Substitute)
United States Patent and
Trademark Office, DOC.
ACTION: Notice of interim patent term
extension.
jlentini on PROD1PC65 with NOTICES
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a fourth one-year interim extension of
the term of U.S. Patent No. 4,826,811.
VerDate Aug<31>2005
18:26 Jun 20, 2006
Jkt 208001
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Patent Ext., P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571) 273–
7755, or by e-mail to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On May 31, 2006, patent owner,
Northfield Laboratories Inc., timely filed
an application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
U.S. Patent No. 4,826,811. The patent
claims the human biological product
PolyHeme (acellular red blood cell
substitute), a method of use of the
biological product, and a method of
manufacturing the biological product.
The application indicates, and the Food
and Drug Administration has confirmed,
that an investigational new drug
application for the human biological
product PolyHeme has been filed and
is currently undergoing regulatory
review before the Food and Drug
Administration for permission to market
or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional year as
required by 35 U.S.C. 156(d)(5)(B).
Because it is apparent that the
regulatory review period will continue
beyond the extended expiration date of
the patent (June 20, 2006), interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,826,611 is granted for a period of one
year from the extended expiration date
of the patent, i.e., until June 20, 2007.
SUPPLEMENTARY INFORMATION:
Dated: June 15, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–9767 Filed 6–20–06; 8:45 am]
COMMODITY FUTURES TRADING
COMMISSION
Comprehensive Review of the
Commitments of Traders Reporting
Program
Commodity Futures Trading
Commission.
AGENCY:
ACTION:
Request for comments.
SUMMARY: The Commitments of Traders
(‘‘COT’’) reports are weekly reports,
published by the Commodity Futures
Trading Commission (‘‘CFTC’’ or
‘‘Commission’’), showing aggregate
trader positions in certain futures and
options markets. Over time, both the
trading activity that is the subject of the
COT reports, and the reports
themselves, have continued to change
and evolve. As part of its ongoing efforts
both to maintain an information system
that reflects changing market
conditions, and to provide the public
with useful information regarding
futures and options markets, the
Commission is undertaking a
comprehensive review of the COT
reporting program. This release is
intended to: (1) Provide useful
background information regarding the
COT reports; (2) lay out various issues
and questions regarding the COT
reports; and (3) solicit public comment
regarding the reports, including
suggestions as to possible changes in the
COT reporting system.
Responses must be received by
August 21, 2006.
DATES:
Written responses should be
sent to Eileen Donovan, Acting
Secretary, Commodity Futures Trading
Commission, Three Lafayette Center,
1155 21st Street, NW., Washington, DC
20581. Responses may also be submitted
via e-mail at secretary@cftc.gov. ‘‘COT
reports’’ must be in the subject field of
responses submitted via e-mail, and
clearly indicated in written
submissions. This document is also
available for comment at https://
www.regulations.gov.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Donald H Heitman, Senior Special
Counsel, Division of Market Oversight,
Commodity Futures Trading
Commission, Three Lafayette Center,
1155 21st Street, NW., Washington, DC
20581. Telephone: 202–418–5041. Email: dheitman@cftc.gov.
SUPPLEMENTARY INFORMATION:
BILLING CODE 3510–16–P
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
35627
E:\FR\FM\21JNN1.SGM
21JNN1
]]>Agencies
[Federal Register Volume 71, Number 119 (Wednesday, June 21, 2006)]
[Notices]
[Page 35627]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9767]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2006-0035]
Grant of Interim Extension of the Term of U.S. Patent No.
4,826,811; PolyHeme[reg] (Acellular Red Blood Cell Substitute)
AGENCY: United States Patent and Trademark Office, DOC.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a fourth one-year interim
extension of the term of U.S. Patent No. 4,826,811.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by e-mail to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On May 31, 2006, patent owner, Northfield Laboratories Inc., timely
filed an application under 35 U.S.C. 156(d)(5) for an interim extension
of the term of U.S. Patent No. 4,826,811. The patent claims the human
biological product PolyHeme[reg] (acellular red blood cell substitute),
a method of use of the biological product, and a method of
manufacturing the biological product. The application indicates, and
the Food and Drug Administration has confirmed, that an investigational
new drug application for the human biological product PolyHeme[reg] has
been filed and is currently undergoing regulatory review before the
Food and Drug Administration for permission to market or use the
product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for an additional year as required
by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory
review period will continue beyond the extended expiration date of the
patent (June 20, 2006), interim extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,826,611 is granted for a period of one year from the
extended expiration date of the patent, i.e., until June 20, 2007.
Dated: June 15, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. E6-9767 Filed 6-20-06; 8:45 am]
BILLING CODE 3510-16-P
